105
Participants
Start Date
November 29, 2018
Primary Completion Date
September 2, 2020
Study Completion Date
October 26, 2020
Etokimab
Administered by subcutaneous injection
Placebo
Administered by subcutaneous injection
Mometasone Furoate Nasal Spray
Mometasone Furoate Nasal Spray (MFNS) was used from 4 weeks prior to Day 1 (Run-in period) through the end of the study. Participants used 2 actuations (50 μg/actuation) in each nostril BID, total daily dose of 400 μg. Participants intolerant to BID intranasal corticosteroids (INCS) could use the lower dose regimen of 1 actuation in each nostril BID, total daily dose of 200 μg.
ENT and Allergy Associates ENTA LLP, New York
Chesapeake Clinical Research Inc., Baltimore
Eastern Virginia Medical School EVMS Medical Group, Norfolk
University of North Carolina Hospitals, Chapel Hill
Charlotte Eye Ear Nose and Throat Associates, Matthews
National Allergy and Asthma Research, North Charleston
Clinical Research Consultants of Atlanta, Suwanee
Intermed Medical Research Center, Miami
Advanced Research Institute, Inc., New Port Richey
Advanced ENT and Allergy, Louisville
Ohio Sinus Institute, Dublin
Allergy, Asthma Sinus Center, SC, Greenfield
Chicago ENT, Chicago
Asthma & Allergy Institute, Little Rock
Allergy Asthma Clinical Research Center, Oklahoma City
Allergy Asthma and Immunology Center P.C., Tulsa
Central States Research, LLC, Tulsa
Ear Nose and Throat Associates of Texas, McKinney
Fort Worth ENT Berkson Medical, Fort Worth
Colorado Allergy Asthma Centers, Denver
Treasure Valley Medical Research, Boise
Intermountain Ear Nose Throat Specialist, Draper
Chrysalis Clinical Research, St. George
Alliance Research Institute, Canoga Park
Allergy & Asthma Medical Group and Research Center, San Diego
DaVinci Research, Roseville
Sacramento Ear Nose and Throat Surgical and Medical Group Inc. - SacENT, Sacramento
Bellingham Asthma Allergy Immunology Clinic, Bellingham
Lead Sponsor
AnaptysBio, Inc.
INDUSTRY